Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pan-tumor × Bevacizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 209 Carcinoma, Non-Small-Cell Lung 124 Breast Neoplasms 111 Glioblastoma 80 Ovarian Neoplasms 76 Rectal Neoplasms 59 Carcinoma, Hepatocellular 59 Brain Neoplasms 53 Neoplasm Metastasis 50 Lung Neoplasms 48 Neoplasms 47 Colonic Neoplasms 45 Glioma 37 Gliosarcoma 32 Fallopian Tube Neoplasms 32 Carcinoma, Renal Cell 31 Adenocarcinoma of Lung 25 Melanoma 24 Recurrence 21 Pancreatic Neoplasms 21 Liver Neoplasms 21 Uterine Cervical Neoplasms 20 Stomach Neoplasms 20 Triple Negative Breast Neoplasms 18 Esophageal Neoplasms 15 Endometrial Neoplasms 15 Kidney Neoplasms 14 Astrocytoma 13 Adenocarcinoma, Bronchiolo-Alveolar 13 Oligodendroglioma 12

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡